搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
12 小时
As new COVID-19 strains emerge, how do vaccine manufacturers keep up with mutations of the ...
New COVID-19 strains are emerging and with it the need for updated vaccines to protect people from the virus. So how do ...
13 小时
on MSN
Is Moderna Inc. (MRNA) the Best QQQ Stock to Buy According to Analysts?
We recently compiled a list of the 10 Best QQQ Stocks to Buy According to Analysts. In this article, we are going to take a ...
16 小时
Is this year’s COVID booster a good match for new variants?
Depending on when you last got vaccinated, that COVID-19 shot may no longer be a good match for the variants expected to ...
1 天
How Bad Is This News for Novavax?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
2 天
Thermo Fisher Scientific (TMO): Resilient Performance Despite Revenue Dip
We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...
2 天
XEC variant 'might escape Covid vaccine defences'
The XEC variant of Covid is quickly becoming the dominant strain of the winter, but the current vaccines may not be as ...
2 天
Cathie Wood的ARK基金买入CRISPR和Intellia股票,卖出Moderna
Cathie Wood的ARK ETF公布了2024年10月18日星期五的每日交易情况,揭示了该基金在生物技术板块的一系列战略性举措。以关注颠覆性创新而闻名的ARK Invest,在CRISPR THERAPEUTICS AG (NASDAQ:CRSP)上进行了最大规模的购买,通过其ARKK和ARKG ETF共计购入33,762股,总价值1,630,367美元。这延续了ARK在前两个交易日大量买入 ...
2 天
美国西北大学起诉Moderna侵犯LNP专利
作者:黄莺美国Moderna公司的专利官司持续不断。一周前,2024年10月12日,葛兰素史克公司(GSK)向美国特拉华州地方法院起诉Moderna,指控其COVID-19疫苗Spikevax以及今年5月份获得FDA批准的RNA呼吸道合胞病毒(RSV ...
Crain's Chicago Business
2 天
Moderna appropriated Northwestern research for COVID vaccine, lawsuit alleges
The Evanston college claims Moderna could not have developed the vaccine as quickly as it did in 2020 without its own ...
Pharmaceutical Technology
2 天
mRNA licensing agreements surge 800% amid GSK lawsuits
An 800% increase in licensing deal values indicates growing confidence in mRNA technology, but some vaccine producers are ...
2 天
BioNTech and Moderna: A tale of two mRNA developers
Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...
BioSpace
2 天
It’s Earnings Season. Here’s What to Watch for Following J&J Beat
This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈